GYRE THERAPEUTICS, INC. (GYRE) Form 8-K — Oct 22, 2026

$GYREForm 8-KItems 5.02, 9.01Filed Oct 22, 2026, 4:01 PM ET0001140361-26-040506Original filing

Gyre Therapeutics entered into new employment agreements on October 16, 2026 with CEO Ying Luo, Ph.D. and CFO Thomas Eastling, formalizing their continued service in their current roles. Dr. Luo receives a $500,000 base salary with a $150,000 target bonus for 2026, while Mr.

Key figures

Ceo base salary: 500000
Cfo base salary: 339066
Ceo target bonus 2026: 150000
Cfo target bonus 2026: 70000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.